drugset / Trial / NCT06867393
Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects
RandomizedParallel-groupTriple-blindOther
Summary
This clinical study aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of HL-003 tablets in healthy subjects. It is conducted in two sequential clinical phases: single-dose and multiple-dose escalation.
Timeline
- Start
- 2025-02-28
- Primary completion
- 2025-08
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HL-003 | Unknown | 25 mg | Oral |
| Comparator | HL-003 | Unknown | 100 mg | Oral |
| Comparator | HL-003 | Unknown | 250 mg | Oral |
| Comparator | HL-003 | Unknown | 500 mg | Oral |
| Comparator | HL-003 | Unknown | 1000 mg | Oral |
| Comparator | HL-003 | Unknown | 1500 mg | Oral |
Indications
No indication recorded.